Cargando…

Immunotherapy: an emerging modality to checkmate brain metastasis

The diagnosis of brain metastasis (BrM) has historically been a dooming diagnosis that is nothing less than a death sentence, with few treatment options for palliation or prolonging life. Among the few treatment options available, brain radiotherapy (RT) and surgical resection have been the backbone...

Descripción completa

Detalles Bibliográficos
Autores principales: Ahmad, Aatiya, Khan, Parvez, Rehman, Asad Ur, Batra, Surinder Kumar, Nasser, Mohd Wasim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10349473/
https://www.ncbi.nlm.nih.gov/pubmed/37454123
http://dx.doi.org/10.1186/s12943-023-01818-7
_version_ 1785073914243710976
author Ahmad, Aatiya
Khan, Parvez
Rehman, Asad Ur
Batra, Surinder Kumar
Nasser, Mohd Wasim
author_facet Ahmad, Aatiya
Khan, Parvez
Rehman, Asad Ur
Batra, Surinder Kumar
Nasser, Mohd Wasim
author_sort Ahmad, Aatiya
collection PubMed
description The diagnosis of brain metastasis (BrM) has historically been a dooming diagnosis that is nothing less than a death sentence, with few treatment options for palliation or prolonging life. Among the few treatment options available, brain radiotherapy (RT) and surgical resection have been the backbone of therapy. Within the past couple of years, immunotherapy (IT), alone and in combination with traditional treatments, has emerged as a reckoning force to combat the spread of BrM and shrink tumor burden. This review compiles recent reports describing the potential role of IT in the treatment of BrM in various cancers. It also examines the impact of the tumor microenvironment of BrM on regulating the spread of cancer and the role IT can play in mitigating that spread. Lastly, this review also focuses on the future of IT and new clinical trials pushing the boundaries of IT in BrM.
format Online
Article
Text
id pubmed-10349473
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-103494732023-07-16 Immunotherapy: an emerging modality to checkmate brain metastasis Ahmad, Aatiya Khan, Parvez Rehman, Asad Ur Batra, Surinder Kumar Nasser, Mohd Wasim Mol Cancer Review The diagnosis of brain metastasis (BrM) has historically been a dooming diagnosis that is nothing less than a death sentence, with few treatment options for palliation or prolonging life. Among the few treatment options available, brain radiotherapy (RT) and surgical resection have been the backbone of therapy. Within the past couple of years, immunotherapy (IT), alone and in combination with traditional treatments, has emerged as a reckoning force to combat the spread of BrM and shrink tumor burden. This review compiles recent reports describing the potential role of IT in the treatment of BrM in various cancers. It also examines the impact of the tumor microenvironment of BrM on regulating the spread of cancer and the role IT can play in mitigating that spread. Lastly, this review also focuses on the future of IT and new clinical trials pushing the boundaries of IT in BrM. BioMed Central 2023-07-15 /pmc/articles/PMC10349473/ /pubmed/37454123 http://dx.doi.org/10.1186/s12943-023-01818-7 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Review
Ahmad, Aatiya
Khan, Parvez
Rehman, Asad Ur
Batra, Surinder Kumar
Nasser, Mohd Wasim
Immunotherapy: an emerging modality to checkmate brain metastasis
title Immunotherapy: an emerging modality to checkmate brain metastasis
title_full Immunotherapy: an emerging modality to checkmate brain metastasis
title_fullStr Immunotherapy: an emerging modality to checkmate brain metastasis
title_full_unstemmed Immunotherapy: an emerging modality to checkmate brain metastasis
title_short Immunotherapy: an emerging modality to checkmate brain metastasis
title_sort immunotherapy: an emerging modality to checkmate brain metastasis
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10349473/
https://www.ncbi.nlm.nih.gov/pubmed/37454123
http://dx.doi.org/10.1186/s12943-023-01818-7
work_keys_str_mv AT ahmadaatiya immunotherapyanemergingmodalitytocheckmatebrainmetastasis
AT khanparvez immunotherapyanemergingmodalitytocheckmatebrainmetastasis
AT rehmanasadur immunotherapyanemergingmodalitytocheckmatebrainmetastasis
AT batrasurinderkumar immunotherapyanemergingmodalitytocheckmatebrainmetastasis
AT nassermohdwasim immunotherapyanemergingmodalitytocheckmatebrainmetastasis